Clinical diagnostics Leverage iCura Diagnostics’ CLIA High Complexity and CAP accreditation to position them as a trusted partner for end-to-end clinical diagnostic services, including IHC, dPCR/qPCR, NGS, and multiplex immunofluorescence, for pharma and biotech clients seeking biomarker validation and translational research collaborations.

Spatial biology niche Target opportunities in tumor microenvironment mapping and spatial phenotyping where their expertise in tissue pathology, high-resolution imaging, and comprehensive analysis can support biomarker discovery, patient stratification, and predictive biomarker development for oncology programs.

Covid diagnostic expansion Explore partnerships or contract opportunities around Covid-19 diagnostic kit development and rapid detection capabilities to align with public health programs and clinics seeking scalable, affordable testing solutions, leveraging their rapid deployment capacity.

SMB collaboration Position iCura as a nimble CRO with end-to-end support including method development and validation, regulatory compliance, and clinical trial logistics to win pilot projects or sponsored studies from smaller biotech firms seeking CRO partners with specialized tissue pathology capabilities.

Growth and scale Despite a small staff, emphasize scalable, high-value services and potential for multi-site or collaborative investments with larger CROs, targeting mid-market biotech and translational research programs where they can offer differentiated imaging, tissue analysis, and integrated assay development at a flexible engagement level.